Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

129.78 -2.13 (-1.61%)
Official Closing Price Updated: 4:10 PM EDT, Sep 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,243,979
Open 129.23
Bid (Size) 128.54 (2)
Ask (Size) 130.25 (1)
Prev. Close 131.91
Today's Range 128.40 - 130.12
52wk Range 86.96 - 148.15
Shares Outstanding N/A
Dividend Yield 1.36%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Evaluating Novo Nordisk: Insights From 8 Financial Analysts
Via Benzinga
Is Merck Stock Undervalued After Its Colossal Earnings Growth?
Merck has seen its earnings invert over the past 12 months, driving earnings grow in its sector. What's going on with this pharma giant? 
Via MarketBeat

Performance

YTD
+27.10%
+27.10%
1 Month
-0.08%
-0.08%
3 Month
-9.64%
-9.64%
6 Month
-1.11%
-1.11%
1 Year
+30.08%
+30.08%

More News

Read More
Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead?
Via The Motley Fool
What the Options Market Tells Us About Novo Nordisk
Via Benzinga
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts
Via Benzinga
Novo Nordisk Unusual Options Activity
Via Benzinga
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
Via Benzinga
Battle Over Compounded Weight-Loss Medications - Sustainability and Regulation
Via Benzinga
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.
Via The Motley Fool
Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors?
Via The Motley Fool
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
Via Chartmill
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
Via Benzinga
How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, Apple
Via Investor's Business Daily
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity
Via Benzinga
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Via Benzinga
Topics Economy
Exposures Interest Rates
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Eli Lilly Launches Discounted Mounjaro And Zepbound As Fight Against Compounded Imitations Escalates Amid Ongoing FDA Shortage Status Debate
Via Benzinga
Exposures Product Safety
Market Thoughts This Labor Day Weekend
Via Talk Markets
Topics Economy
Exposures Interest Rates
Ozempic: Unexpected Anti-Aging Miracle Drug? Researchers Reveal Surprising Potential
Via Benzinga
3 No-Brainer Stocks to Buy in September
Via The Motley Fool
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
Via The Motley Fool
Judge's Early Ruling May Shape Outcome In Ozempic, Wegovy Lawsuits
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Novo Nordisk Touts Encouraging Wegovy Data To Lower Risk Of Severe Complications In Heart Failure Patients
Via Benzinga
This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.